Pancreatic Cancer Research

ResearcherUniversity of MissouriActive in the last 2 years

Guangfu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9817-568X; OpenAlex author ID A5086997032. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 10

  1. Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy. Last author DOI 10.1016/j.omton.2025.201080↗
  2. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers16081470↗
  3. Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy. Last author DOI 10.3390/cancers16101808↗
  4. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Last author DOI 10.1016/j.canlet.2023.216457↗
  5. Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Last author DOI 10.1016/j.tranon.2021.101262↗
  6. LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. Last author DOI 10.3389/fcell.2021.647387↗
  7. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. Co-author DOI 10.7150/thno.53102↗
  8. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Last author DOI 10.1016/j.canlet.2019.04.022↗
  9. Data on the function of CDH17 in pancreatic cancer growth. Last author DOI 10.1016/j.dib.2019.104332↗
  10. Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis. Last author DOI 10.1016/j.canlet.2017.03.024↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric T. Kimchi · 6 shared papers, 2021–2025 · strength 1.16
  2. Olamide Tosin Olaoba · 3 shared papers, 2024–2025 · strength 0.72
  3. Kun Cheng · 4 shared papers, 2021–2025 · strength 0.68
  4. Ming Jun Yang · 3 shared papers, 2023–2024 · strength 0.66
  5. Xinjian Liu · 3 shared papers, 2019–2025 · strength 0.44
  6. Yi Miao · 3 shared papers, 2019–2025 · strength 0.44
  7. Nan Lyu · 2 shared papers, 2023–2025 · strength 0.41
  8. Hao Yuan · 3 shared papers, 2019–2021 · strength 0.36
  9. Jussuf T. Kaifi · 3 shared papers, 2019–2022 · strength 0.35
  10. Ernest Ramsay Camp · 1 shared paper, 2025 · strength 0.24
  11. Jing Zhou · 1 shared paper, 2023 · strength 0.18
  12. Chiswili Yves Chabu · 1 shared paper, 2022 · strength 0.15
  13. Jing Zhou · 1 shared paper, 2022 · strength 0.15
  14. Kuirong Jiang · 2 shared papers, 2017–2019 · strength 0.15
  15. Yuanke Li · 1 shared paper, 2021 · strength 0.15
  16. Kuirong Jiang · 1 shared paper, 2021 · strength 0.11
  17. Min Li · 1 shared paper, 2019 · strength 0.09
  18. Zipeng Lu · 1 shared paper, 2017 · strength 0.06
  19. Yang Feng Wu · 1 shared paper, 2017 · strength 0.06
  20. Pengfei Wu · 1 shared paper, 2017 · strength 0.06
  21. Yi Miao · 1 shared paper, 2017 · strength 0.06
  22. Baobao Cai · 1 shared paper, 2017 · strength 0.06
  23. Dong Qian · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.